BCL2 and diffuse large B-cell lymphoma: Although p65 nuclear expression may not be a strong prognostic marker in overall DLBCL, we found p65 hyperactivation (IHC ≥50%) had significant adverse impact on survival of patients with stage I/II DLBCL independent of cell-of-origin and TP53 mutation status, even though it was not associated with apparent genetic or phenotypic abnormalities, such as TP53 mutations, MYC/BCL2 translocation, and Myc/Bcl-2 overexpression.